Evidence map›Paper›PMID 38929613›Full record

ArticleMedicina (Kaunas, Lithuania)2024

Grading Challenges and Prognostic Insights in Chromophobe Renal Cell Carcinoma: A Retrospective Study of 72 Patients.

Dimitrios Papanikolaou, Ioannis Sokolakis, Kyriakos Moysidis, Nikolaos Pyrgidis, Mattheos Bobos, Soultana Meditskou, Konstantinos Hatzimouratidis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dimitrios PapanikolaouSecond Department of Urology, Medical School, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.ORCID 0000-0001-6669-5982
Ioannis SokolakisSecond Department of Urology, Medical School, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Kyriakos MoysidisSecond Department of Urology, Medical School, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Nikolaos PyrgidisDepartment of Urology, University Hospital, LMU Munich, 80539 Munich, Germany.
Mattheos BobosDepartment of Biomedical Sciences, School of Health Sciences, International Hellenic University, 570 01 Thessaloniki, Greece.ORCID 0000-0001-5662-9201
Soultana MeditskouLaboratory of Histology and Embryology, Medical School, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.
Konstantinos HatzimouratidisSecond Department of Urology, Medical School, Aristotle University of Thessaloniki, 541 24 Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chromophobe RCC (ChRCC) carries the best prognosis among all RCC subtypes, yet it lacks a proper grading system. Various systems have been suggested in the past, causing much controversy, and Avulova et al. recently proposed a promising four-tier grading system that takes into consideration tumor necrosis. Dysregulation of the mammalian target of the rapamycin (mTOR) pathway plays a key role in ChRCC pathogenesis, highlighting its molecular complexity. The present retrospective study aimed to evaluate the prognostic factors associated with a more aggressive ChRCC phenotype.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsNeoplasm GradingTOR Serine-Threonine KinasesAdultAgedBiomarkers, TumorDeubiquitinating Enzyme CYLDFemaleHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedPrognosisRetrospective StudiesBiomarkers, TumorCYLD protein, humanDeubiquitinating Enzyme CYLDMTOR protein, humanTOR Serine-Threonine Kinaseschromophobenephrectomyprognosisrenal cell carcinoma

Identifiers

PMID38929613
PMCPMC11205766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.